

Oncotype DX Breast Recurrence Score® Test

Informing Adjuvant Treatment Decisions for early-stage, HR+, HER2- breast cancer

Oncotype DX®

Prospective Randomized Clinical Trials	Number of Patients Randomized=6711 Oncotype DX: TAILORx ¹ (9-yr results)	✓
Validated for Prediction of Chemotherapy Benefit^{1,3-6} (N- and N+)		✓
Validated for Prognosis⁷⁻¹²	Node Negative and Node Positive	✓
	Pre-Menopausal	✓
	Post-Menopausal	✓
	Homogeneous Populations	✓
Inclusion in Major International Guidelines	NCCN Guidelines® Algorithm: “Strongly Consider” ¹³	✓
	NCCN Guidelines® Category: “Preferred” (Category 1) ¹³	✓
	NICE (UK) Diagnostics Guidance ¹⁴	✓
	ASCO “Strong Recommendation” ¹⁵	✓
	ESMO ¹⁶ , St. Gallen ¹⁷ and AGO ¹⁸	✓
Inclusion in AJCC 8th Edition Cancer Staging Table for assignment of Pathological Prognostic Stage Group 1A¹⁹		✓
Supportive & Prospective Outcomes Evidence (number of N- & N+ patients)^{1, 3, 5, 7-9, 11-12, 20-23}		99,737
Additional Clinical Evidence	DCIS, Neoadjuvant, Late Recurrence, Adjuvant Hormonal Therapy Benefit	✓

NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed (January 15, 2020). To view the most recent and complete version of the guideline, go online to NCCN.org. ASCO is a trademark of the American Society of Clinical Oncology. AJCC is a trademark of the American College of Surgeons. NCCN, ASCO, ESMO, St. Gallen, NICE, AGO and AJCC do not endorse any product or therapy. **References:** **1.** Sparano et al. *N Engl J Med.* 2018. **2.** Nitz et al. *Breast Cancer Res Treat.* 2017. **3.** Paik et al. *J Clin Oncol.* 2006. **4.** Sparano et al. *J Clin Oncol.* 2006. **5.** Albain et al. *Lancet Oncol.* 2010. **6.** Geyer et al. *npj Breast Cancer.* 2018. **7.** Paik et al. *N Engl J Med.* 2004. **8.** Habel et al. *Breast Cancer Res.* 2006. **9.** Dowsett et al. *J Clin Oncol.* 2010. **10.** Toi et al. *Cancer.* 2010. **11.** Sparano et al. *N Engl J Med.* 2015. **12.** Sparano et al. *JAMA Oncol.* 2019. **13.** NCCN Clinical Practice Guidelines in Oncology for Breast cancer. V3. 2020. **14.** NICE Guidelines. <http://www.nice.org.uk/guidance/dg34>. December 2018. **15.** Andre et al. *J Clin Oncol.* 2019. **16.** Cardoso et al. *Ann Oncol.* 2019. **17.** Burnstein et al. *Ann Oncol.* 2019. **18.** www.ago-online.de Guidelines Breast Cancer Version 21.11.2018. **19.** AJCC Cancer Staging Manual, Eighth Edition updated 9-Nov-17. **20.** Stemmer et al. *npj Breast Cancer.* 2017. **21.** Stemmer et al. *npj Breast Cancer.* 2017. **22.** Hortabagyi et al. SABCs 2018. **23.** Nitz et al. *Breast Cancer Res Treat.* 2017.

Oncotype DX Breast Recurrences Score, Oncotype DX, are trademarks of Genomic Health Inc, an Exact Sciences corporation.
All other trademarks are the property of their respective owners. © 2020 Exact Sciences, Inc. All rights reserved. GH11484_0220

ONLY ONCOTYPE DX[®] TEST

TAILORx:
Definitive results,
consistent
outcomes¹⁻³



YES
CHEMOTHERAPY

NO
CHEMOTHERAPY

**It's never
been as clear**

to predict chemotherapy benefit for
patients with early-stage breast cancer¹⁻⁴

oncotypeDX[®]
Breast Recurrence Score

References: 1. Sparano et al. *N Engl J Med.* 2015. 2. Sparano et al. *N Engl J Med.* 2018. 3. Sparano et al. *JAMA Oncol.* 2019. 4. Paik et al. *J Clin Oncol.* 2006.